3 days Ago By ABMN Staff
CG Oncology, Inc. ( NASDAQ:CGON – Free Report ) – Research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for CG Oncology in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst J.
Schimmer now anticipates that the company will post earnings per share of ($1.29) for the year, up from their previous estimate of ($1.32).
The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. CG Oncology ( NASDAQ:CGON – Get Free Report ) last released its quarterly earnings results on Tuesday, November 12th.
The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.
06. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.
30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.
97%. Get Our Latest Stock Report on CGON CG Oncology Trading Up 1.0 % Shares of NASDAQ CGON opened at $33.
21 on Monday. The company’s 50-day simple moving average is $36.61 and its 200-day simple moving average is $34.
61. CG Oncology has a 52-week low of $25.77 and a 52-week high of $50.
23. Institutional Investors Weigh In On CG Oncology Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology in the 1st quarter valued at $492,000.
Vanguard Group Inc. purchased a new position in CG Oncology during the first quarter worth about $97,678,000. Ameritas Investment Partners Inc.
purchased a new position in CG Oncology during the first quarter worth about $102,000. American International Group Inc. acquired a new stake in shares of CG Oncology during the first quarter valued at about $13,443,000.
Finally, Decheng Capital LLC purchased a new stake in shares of CG Oncology in the 1st quarter valued at approximately $239,642,000. Institutional investors and hedge funds own 26.56% of the company’s stock.
Insider Activity In other news, Director Hong Fang Song sold 650,455 shares of CG Oncology stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $35.36, for a total transaction of $23,000,088.
80. Following the sale, the director now owns 586,982 shares of the company’s stock, valued at approximately $20,755,683.52.
The trade was a 52.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link .
About CG Oncology ( Get Free Report ) CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. Featured Articles Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.
com's FREE daily email newsletter ..
